5-drug adjuvant chemotherapy for breast cancer

✍ Scribed by Robert W. Carey; W. Davies Sohier; Sheldon Kaufman; Sigmund A. Weitzman; Rita M. Kelley; Robert A. Lew; Elkan Halpern

• Publisher: John Wiley and Sons
• Year: 1979
• Tongue: English
• Weight: 522 KB
• Volume: 44
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(197907)44:1<35::aid-cncr2820440107>3.0.co;2-s

✦ Synopsis

A series of 41 patients at the MGH who received B-drug chemotherapy, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone, (CMF VP) as adjuvant to surgical treatment of operable breast cancer with 4 or more positive axillary nodes is compared to an analogous group of patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) reported by Bonadonna et al. ' in an effort to assess the contribution of the treatment program to disease control.

The MGH pattern of disease free survival closely parallels that of Bonadonna? Median disease-free survival among the 24 patients who have not recurred is 27 months; among those who recurred 18 months. The analogous medians for treated patients in the Bonadonna study are 24 months and 16 months, as compared to 27 months and 8 months for his nontreated controls. The treatment program, carried out over a two year period, was well tolerated with excellent patient compliance. There was no significant impact, however, in the disease-free survival of postmenopausal patients. While use of this regimen improved disease-free survival in premenopausal individuals, it is clear that a great deal of room for improvement exists, and newer regimens should be investigated.

Cancer 44:35-41, 1979. HE STUDY OF A SERIES of 41 patients re-T ceiving 5-drug adjuvant chemotherapy, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone, (CMF-VP) as adjuvant to surgical treatment of operable breast cancer reveals that the pattern of disease-free survival of patients with 4 or more involved axillary nodes closely parallels patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in a report by Bonadonna et al.' This report describes a series of patients beginning treatment at the Massachusetts